Is an SGLT2 inhibitor right for your patient with type 2 diabetes?

被引：0
作者：
Lisenby, Katelin M. [1 ]
Meyer, Allison [1 ]
Slater, Nicole A. [1 ]
机构：
[1] Auburn Univ, Harrison Sch Pharm, Dept Pharm Practice, Tuscaloosa, AL USA
来源：
JOURNAL OF FAMILY PRACTICE | 2016年 / 65卷 / 09期
关键词：
INADEQUATE GLYCEMIC CONTROL; METFORMIN PLUS SULFONYLUREA; LONG-TERM EFFICACY; ADD-ON THERAPY; DOUBLE-BLIND; BACKGROUND METFORMIN; SAFETY; EMPAGLIFLOZIN; PLACEBO; CANAGLIFLOZIN;
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：587 / 593
页数：7
相关论文
共 50 条
  • [1] SGLT2 inhibitors in the treatment of type 2 diabetes
    Hasan, Farhad M.
    Alsahli, Mazen
    Gerich, John E.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 104 (03) : 297 - 322
  • [2] Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis
    Ruanpeng, Darin
    Ungprasert, Patompong
    Sangtian, Jutarat
    Harindhanavudhi, Tasma
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2017, 33 (06)
  • [3] SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
    Scheen, Andre J.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (12) : 1879 - 1904
  • [4] Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
    Nauck, Michael A.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1335 - 1380
  • [5] DAPAGLIFLOZIN, AN SGLT2 INHIBITOR FOR THE TREATMENT OF TYPE 2 DIABETES
    Demaris, K. M.
    White, J. R.
    DRUGS OF TODAY, 2013, 49 (05) : 289 - 301
  • [6] The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
    McGill, Janet B.
    DIABETES THERAPY, 2014, 5 (01) : 43 - 63
  • [7] The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis
    Cai, Xiaoling
    Yang, Wenjia
    Gao, Xueying
    Chen, Yifei
    Zhou, Lingli
    Zhang, Simin
    Han, Xueyao
    Ji, Linong
    OBESITY, 2018, 26 (01) : 70 - 80
  • [8] Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes A meta-analysis
    Zou, Cai-Yan
    Liu, Xue-Kui
    Sang, Yi-Quan
    Wang, Ben
    Liang, Jun
    MEDICINE, 2019, 98 (49)
  • [9] Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 Diabetes
    Nigro, Stefanie C.
    Riche, Daniel M.
    Pheng, Michelle
    Baker, William L.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (10) : 1301 - 1311
  • [10] The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
    Garcia-Ropero, Alvaro
    Badimon, Juan J.
    Santos-Gallego, Carlos G.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (12) : 1287 - 1302
12345